logo
  Join        Login             Stock Quote

FDA OKs Expanded Use Of Bayer/Onyx Drug For Rare Gastrointestinal Tumor

 February 25, 2013 02:51 PM
 


(By Balachander) The U.S. Food and Drug Administration (FDA) has approved the expanded use of Bayer AG's drug Stivarga to treat a rare type of gastrointestinal tract cancer.

Stivarga, which was approved in September 2012 to treat colorectal cancer, is the third drug cleared by the U.S. health regulators to treat gastrointestinal stromal tumors (GIST).

Germany-based Bayer and South San Francisco, California-based Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) co-promote Stivarga - known as regorafenib - in the United States.

The FDA on Monday approved Stivarga for patients whose GIST cannot be surgically removed and no longer respond to other FDA-approved treatments Novartis' (NVS) Gleevec and Pfizer's (PFE) Sutent.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

GIST is a tumor in which cancerous cells form in the tissues of the gastrointestinal tract, part of the body's digestive system. According to the National Cancer Institute, an estimated 3,300 to 6,000 new cases of GIST occur yearly in the United States, most often in older adults.

According to the FDA, clincial study results showed patients taking Stivarga had a delay in tumor growth that was, on average, 3.9 months later than patients who were given a placebo.

[Related -Jobs Growth Tepid At Best]

The most common side effects reported in patients treated with Stivarga were weight loss, stomach pain, rash, fever, hand-foot syndrome, diarrhea, loss of appetite, high blood pressure and nausea.

Onyx shares inched 0.13 percent higher to trade at $78.40 at 2.38 pm ET on Monday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageArcelorMittal SA (ADR)(MT): Steel Stocks about to Get Red Hot

For the second consecutive day, a major broker upgraded a steel company by advancing their recommendation read on...

article imageExpress, Inc. (EXPR) Q2 Earnings Preview: Out of Style

Express, Inc. (NYSE:EXPR) will conduct a conference call to discuss its second quarter fiscal 2014 results read on...

article imageSmith & Wesson Holding Corp. (SWHC) Q1 Earnings Preview: Above Target

Smith & Wesson Holding Corp. (NASDAQ:SWHC) plans to release its first quarter fiscal 2015 financial results read on...

article imageUnited States Steel Corporation (NYSE:X): Turning $50 Says Credit Suisse

United States Steel Corporation (NYSE:X) is rolling today; up nearly 2.5% thanks mostly to an upgrade from read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.